

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peng Cho TANG et al.
Title: INDOLINONE COMBINATORIAL LIBRARIES AND RELATED
PRODUCTS AND METHODS FOR THE TREATMENT OF
DISEASE
Prior Appl. No.: 10/076,621
Prior Appl. Filing Date: 02/19/2002
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003*.

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 10/076,621, filed 02/19/2002, which is a continuation of application Serial No. 09/617,529, filed 07/13/2000, which is a divisional of application Serial No. 08/915,366, filed 08/20/1997. As provided in 37 CFR

§1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent applications.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Date

2/24/04

FOLEY & LARDNER


Customer Number: 22428

Telephone: (202) 672-5475

Facsimile: (202) 672-5399

Respectfully submitted,

By



Beth A. Burrous

Attorney for Applicant

Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Prior Application Number	10/076,621
				Prior Appl. Filing Date	02/19/2002
				First Named Inventor	Peng Cho TANG
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-1150
Sheet	1	of	26		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	Re 36,256		Spada et al.	07/20/1999	
	A2	2,872,372		Hull	02/03/1959	
	A3	2,968,557		Burgardt et al.	01/17/1961	
	A4	4,002,749		Rovnyak	01/11/1977	
	A5	4,053,613		Rovnyak et al.	10/11/1977	
	A6	4,376,110		David et al.	03/08/1983	
	A7	4,642,309		Michel et al.	02/10/1987	
	A8	4,826,847		Michel et al.	05/02/1989	
	A9	4,853,403		Shiraishi et al.	08/01/1989	
	A10	4,868,304		Larock et al.	09/19/1989	
	A11	4,966,849		Vallee et al.	10/30/1990	
	A12	4,971,996		Shiraishi et al.	11/20/1990	
	A13	5,051,417		Nadler et al.	09/24/1991	
	A14	5,057,538		Shiraishi et al.	10/15/1991	
	A15	5,089,516		Shiraishi et al.	02/18/1992	
	A16	5,124,347		Connor et al.	06/23/1992	
	A17	5,202,341		Shiraishi et al.	04/13/1993	
	A18	5,206,261		Kawaguchi et al.	04/1993	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)				Complete if Known	
				Prior Application Number	10/076,621
				Prior Appl. Filing Date	02/19/2002
				First Named Inventor	Peng Cho TANG
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-1150
Sheet	2	of	26		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A19	5,217,999		Levitzki et al.	06/08/1993	
	A20	5,302,606		Spada et al.	04/12/1994	
	A21	5,322,950		Sircar et al.	06/1994	
	A22	5,330,992		Eissenstat et al.	07/19/1994	
	A23	5,374,652		Buzzetti et al.	12/20/1994	
	A24	5,382,593		Le Baut	01/1995	
	A25	5,397,787		Buzzetti et al.	03/14/1995	
	A26	5,409,949		Buzzetti et al.	04/1995	
	A27	5,463,052		Haga et al.	10/31/1995	
	A28	5,786,488		Tang et al.	07/28/1998	
	A29	5,792,783		Tang	08/11/1998	
	A30	5,840,745		Buzzetti et al.	11/24/1998	
	A31	5,849,710		Battistini et al.	12/15/1998	
	A32	5,880,141		Tang et al.	03/09/1999	
	A33	5,883,113		Tang et al.	03/16/1999	
	A34	5,883,116		Tang et al.	03/16/1999	
	A35	5,886,020		Tang et al.	03/23/1999	
	A36	6,130,238		Tang et al.	10/2000	
	A37	6,147,106		Tang et al.	11/2000	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Prior Application Number	10/076,621
				Prior Appl. Filing Date	02/19/2002
				First Named Inventor	Peng Cho TANG
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	26	Attorney Docket Number	034536-1150

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A38	AU	286870		IMPERIAL CHEMICAL INDUSTRIES OF AUSTRALIA AND NEW ZEALAND LIMITED	05-11-1967		
	A39	CA	2,012,634	A1	UNIVERSITY OF BRITISH COLUMBIA	09-20-1991		
	A40	DE	878,539		Von FREYBERG, et al.	06-05-1953		X
	A41	DE	2,159,360	A	BAYER AG	06-14-1973		X
	A42	DE	2,159,361	A	BAYER AG	06-14-1973		X
	A43	DE	2,159,362		BAYER AG	06-14-1973		
	A44	DE	2,159,363	A	BAYER AG	06-14-1973		X
	A45	DE	2,321,656	A	COLGATE-PALMOLIVE CO.	11-15-1973		X
	A46	DE	3,426,419	A	BOEHRINGER MANNHEIM GMBH	01-23-1986		X
	A47	EP	0 252 713	B1	PFIZER INC.	01-13-1988		
	A48	EP	0 351 213	A2	LES LABORATOIRES BEECHAM S.A.	01-17-1990		
	A49	EP	0 525 472	A2	FARMITALIA CARLO ERBA SRL	02-03-1993		
	A50	EP	0 566 226	B1	ZENECA LIMITED	10-20-1993		
	A51	EP	0 580 502	B1	ADIR ET COMPAGNIE	01-26-1994		X
	A52	EP	0 626 377	B1	SHIONOGI & CO., LTD.	11-30-1994		
	A53	EP	0 632 102	A1	BAYER AG	01-04-1995		X

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Prior Application Number	10/076,621
				Prior Appl. Filing Date	02/19/2002
				First Named Inventor	Peng Cho TANG
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-1150
Sheet	4	of	26		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A54	EP	0 662 473	A1	PHARMACIA S.P.A.	07-12-1995		
	A55	EP	0 788 890	A1	AGFA-GEVAERT	08-13-1997		
	A56	FR	1.398.224		IMPERIAL CHEMICAL INDUSTRIES LIMITED	05-07-1965		X
	A57	FR	2.689.397	A1	ADIR ET COMPAGNIE	10-08-1993		X
	A58	HU	65452		RICHTER GEDEON BEGYESZETI GYAR RT	06-28-1994		
	A59	JP	62-29570	A	KANEGAFUCHI CHEM KK	02-07-1987		X
	A60	JP	62-39564	A	KANEGAFUCHI CHEM KK	02-20-1987		X
	A61	JP	63-141955	A	KANEGAFUCHI CHEM KK	06-14-1988		X
	A62	JP	5-58894	A	KANEKA CORP	03-09-1993		X
	A63	GB	809,691		Roy HULL	03-04-1959		
	A64	GB	835,473		Norman SENIOR	05-18-1960		
	A65	WO	88/07035	A1	KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA	09-22-1988		
	A66	WO	91/13055	A2	FARMITALIA CARLO ERBA SRL	09-05-1991		
	A67	WO	91/15495	A1	PFIZER INC.	10-17-1991		
	A68	WO	92/03736	A1	SEIKAGAKU KOGYO KABUSHIKI KAISHA	03-05-1992		
	A69	WO	92/07830	A2	PFIZER INC.	05-14-1992		
	A70	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL	11-26-1992		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Prior Application Number	10/076,621
				Prior Appl. Filing Date	02/19/2002
				First Named Inventor	Peng Cho TANG
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-1150
Sheet	5	of	26		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A71	WO	92/21660	A1	PFIZER INC.	12-10-1992		
	A72	WO	93/01182	A1	FARMITALIA CARLO ERA SRL	01-21-1993		
	A73	WO	93/23040	A1	MERCK & CO., INC.	11-25-1993		
	A74	WO	94/03427	A1	WARNER-LAMBERT COMPANY	02-17-1994		
	A75	WO	94/10202	A1	GENENTECH, INC.	05-11-1994		
	A76	WO	94/14808	A1	FARMITALIA CARLO ERBA SRL	07-07-1994		
	A77	WO	95/01349	A1	FARMITALIA CARLO ERBA SRL	01-12-1995		
	A78	WO	95/14667	A1	PFIZER INC.	06-01-1995		
	A79	WO	95/17181	A1	PHARMACIA S.P.A.	06-29-1995		
	A80	WO	95/24190	A2	SUGEN, INC.	09-14-1995		
	A81	WO	96/00226	A1	PHARMACIA S.P.A.	01-04-1996		
	A82	WO	96/16964	A1	PHARMACIA S.P.A.	06-06-1996		
	A83	WO	96/22976	A1	PHARMACIA S.P.A.	08-01-1996		
	A84	WO	96/32380	A1	PHARMACIA S.P.A.	10-17-1996		
	A85	WO	96/40116	A1	SUGEN, INC.	12-19-1996		
	A86	WO	97/25986	A1	TAIHO PHARMACEUTICAL CO., LTD.	07-24-1997		
	A87	WO	97/36867	A1	PFIZER, INC.	10-09-1997		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 6 of 26	Attorney Docket Number	034536-1150	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A88	WO	98/07695	A1	SUGEN, INC.	02-26-1998		
	A89	WO	98/07835	A2	SUGEN, INC.	02-26-1998		
	A90	WO	98/45708	A1	SUGEN, INC.	10-15-1998		
	A91	WO	98/50356	A1	SUGEN, INC.	11-12-1998		
	A92	WO	98/56376	A1	SUGEN, INC.	12-17-1998		
	A93	WO	99/10325	A1	GLAXO GROUP LIMITED	03-04-1999		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	A94	Abramovitch and Hey, "Internuclear cyclisation. Part VIII. Naphth[3:2:1-cd]oxindoles," <u>J. Chem. Soc.</u> pp. 1697-1703 (1954)			
	A95	Abramovitch et al., "A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement," <u>Chemistry and Industry</u> 44:1871 (1967)			
	A96	Abramovitch, Beilstein Reg. No. 236050, <u>J. Chem. Soc.</u> , pages 1697, 1700 (1954)			
	A97	Akbasak and Suner-Akbasak et al., "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992)			
	A98	Andreani et al., "In Vivo Cardiotoxic Activity of Pyridylmethylene-2-indolinones," <u>Arzneimittel-Forschung Drug Research</u> 48 (II): 727-729(1998)			
	A99	Andreani et al., "Potential antitumor agents. 25[1]. Synthesis and cytotoxic activity of 3-(2-chloro-3-indolylmethlene) 1,3-Dyhydroindol-2-ones," <u>AntiCancer Research</u> 16:3585-3588 (1996)			
	A100	Andreani et al., "Synthesis and cardiotoxic activity of 2-indolinones," <u>Eur. J. Med. Chem.</u> 25:187-190 (1990)			
	A101	Andreani et al., "Synthesis and cardiotoxic activity of 2-indolinones," <u>Chemical Abstracts</u> , Vol. 113, abstract no. 78106 (1990)			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 <i>(use as many sheets as necessary)</i>		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	7	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A102	Andreani et al., "Synthesis and cardiotoxic activity of 2-indolinones bearing pyridyl groups," <u>Eur. J. Med. Chem.</u> 28:653-657 (1993)	
	A103	Andreani et al., "Synthesis and cardiotoxic activity of pyridylmethylene-2-indolinones," <u>Eur. J. Med. Chem.</u> 27:167-170 (1992)	
	A104	Andreani et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo [2, 1-b]thiazolymethylene)-2-indolinones," <u>Eur. J. Med. Chem.</u> 32:919-924 (1997)	
	A105	Andreani et al., "Synthesis of lacatams with potential cardiotoxic activity," <u>Eur. J. Med. Chem.</u> 28:825-829 (1993)	
	A106	Arteaga et al., "Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice," <u>J. Clin. Invest.</u> 84:1418-1423 (1989)	
	A107	Arvidsson et al., "Tyr-716 in the Platelet-Derived Growth Factor β -Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," <u>Molecular and Cellular Biology</u> 14:6715-6726 (1994)	
	A108	Autrey and Tahk, "The Synthesis and Stereochemistry of Some Isatylideneacetic Acid Derivatives," <u>Tetrahedron</u> 23:901-917 (1967)	
	A109	Bahner et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," <u>J. Med. Chem.</u> 12:721-722 (1969)	
	A110	Barnfield et al., "Diels-Alder Reactions of Oxindolylideneacetone," <u>J. Chem. Soc. (C)</u> pp. 1028-1030 (1966)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	8	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A111	Baserga, "Oncogenes and the strategy of growth factors," <u>Cell</u> 79:927-930 (1994)	
	A112	Baserga, "The insulin-like growth factor I receptor: a key to tumor growth?" <u>Cancer Res.</u> 55:249-252 (1995)	
	A113	Beilstein Reg. No. 235647 (1997)	
	A114	Beilstein Reg. No. 233511 (1997)	
	A115	Beilstein Reg. No.: 252929 (1923)	
	A116	Blake and Jaques, "Anisotropic Effects in alpha-substituted methoxystilbenes," <u>J. Chem. Soc. Perkin II</u> pp. 1660-1663 (1973)	
	A117	Blake and Jaques, "Anisotropic Effects in alpha-substituted methoxystilbenes," <u>Chemical Abstracts</u> , Vol. 80, abstract no. 26692 (1974)	
	A118	Bolen, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993)	
	A119	Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	9	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A120	Bonner et al., "Structure and Biological Activity of Human Homologs of the <i>raf/mil</i> Oncogene," <u>Molecular and Cellular Biology</u> 5:1400-1407 (1986)	
	A121	Borsche et al., "Über nielkernige kondensierte systeme mit heterocyclischen ringen," <u>Liebigs Ann. Chem.</u> 550:160-174 (1941)	
	A122	Buzzetti et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," II <u>Farmaco</u> 48(5):615-636 (1993)	
	A123	Cance et al., "Novel Protein Kinases Expressed in Human Breast Cancer," <u>Int. J. Cancer</u> 54:571-577 (1993)	
	A124	Canoira and Rodriguez, "Synthesis of Oxindole Derivatives from N-Alkenyl-o-Chloroanilides with Zero-Valent Nickel Complex," <u>J. Heterocyclic Chem.</u> 22:1511-1518 (1985)	
	A125	Carpeneo et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs," <u>Analytical Biochemistry</u> 244:74-79 (1997)	
	A126	Chao, "Growth Factor Signaling: Where is the Specificity?" <u>Cell</u> 68:995-997 (1992)	
	A127	Chatten et al., "Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted trans-3-Benzylideneindol-2(3H)-ones," <u>J. Chem. Soc. Perkin II</u> pp. 469-473 (1973)	
	A128	Chen et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ -Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron," <u>Chinese Journal of Physiology</u> 40(3):149-156 (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	10	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A129	Claesson-Welsh, "Signal Transduction by the PDGF Receptors," <u>Progress in Growth Factor Research</u> 5:37-54 (1994)	
	A130	Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>J. Chem. Soc. Perkin II</u> pp. 615-619 (1984)	
	A131	Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>Chemical Abstracts</u> , Vol. 101, abstract no. 37875 (1984)	
	A132	Coda et al., "3-(4-methylbenzylidene)-1-,3-dihydroindol-2-one," <u>J. Chem. Soc. Perkin II</u> , Database Crossfire, Beilstein Ref. No. 6-21, 4: 615-620 (1984)	
	A133	Coppola et al., "A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 14:4588-4595 (1994)	
	A134	Daisley, "Thin-layer chromatographic separation of some substituted 3-benzylidene-indol-2(3H)-ones," <u>J. Chromatography</u> 100:240-242 (1974)	
	A135	Daisley, "Thin-layer chromatographic separation of some substituted 3-benzylidene-indol-2(3H)-ones," <u>Chemical Abstracts</u> Vol. 82, abstract no. 72891 (1975)	
	A136	Damiani et al., "Inhibition of Cooper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," <u>Biochemical Pharmacology</u> 48(6):1155-1161 (1994)	
	A137	Dati et al., "Inhibition of <i>c-erbB-2</i> oncogene expression by estrogens in human breast cancer cells," <u>Oncogene</u> 5:1001-1006 (1990)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	11	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A138	Davis et al., "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," <u>Journal of Medicinal Chemistry</u> 16(9):1043-1045 (1973)	
	A139	Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>J. Immunol. Methods</u> 15:61-69 (1988)	
	A140	De Vries et al., "The <i>fms</i> -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991 (1992)	
	A141	Dickson et al., "Tyrosine kinase receptor-nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992)	
	A142	Elliot, "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," Database Crossfire, Beilstein Ref. No. 5-24, March 19, 1991, XP 002049951	
	A143	Elliott and Rivers, "Reduction of some oxindolylidene derivatives to 3-substituted oxindoles by sodium borohydride," <u>J. Organic Chem.</u> 29:2438-2440 (1964)	
	A144	Fantl et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423 (1992)	
	A145	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human or Epidermal Growth Factor Receptor or HER2/ <i>neu</i> Gene Product" <u>Cancer Research</u> 50:1550-1558 (1990)	
	A146	Ferrara and Henzel, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research Communications</u> 161:851-858 (1989)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	12	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A147	Fingl and Woodbury, Chapter 1, pp. 1-46 in <u>The Pharmacological Basis of Therapeutic</u> (5 th edition), eds. Goodman et al., MacMillan Publishing Co., Inc., New York (1975)	
	A148	Floege et al., "Factors involved in the regulation of mesangial cell proliferation <i>in vitro in vivo</i> ," <u>Kidney International</u> 43S:47-54 (1993)	
	A149	Floege et al., "Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis," <u>Kidney International</u> 43:369-380 (1993)	
	A150	Folkman and Shing, "Angiogenesis," <u>J. Biol. Chem.</u> 267:10931-10934 (1992)	
	A151	Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?" <u>Journal of the National Cancer Institute</u> 82:4-6 (1990)	
	A152	Folkman, "Ch. 24. Angiogenesis," <u>Congress of Thrombosis and Haemostasis</u> (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)	
	A153	Folkman, "Tumor Angiogenesis: Therapeutic Implications" <u>New England J. Medicine</u> 285:1182-1186 (1971)	
	A154	Gazit et al., "Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2-neu tyrosine-kinases," <u>J. Med. Chem.</u> 34(6):1896-1907 (1991)	
	A155	Gennaro (editor), <u>Remington's Pharmaceutical Sciences</u> (1990)(TABLE OF CONTENTS ONLY)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 <i>(use as many sheets as necessary)</i>		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	13	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A156	Goldring and Goldring, "Cytokines and cell growth control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991)	
	A157	Gottardis et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen," <u>J. Steroid Biochem.</u> 30(1-6):311-314 (1988)	
	A158	Graziani et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger," <u>The Journal of Biological Chemistry</u> 268(13):9165-9168 (1993)	
	A159	Hewgill and Stewart, "Phenanthrene-4,5-quinones: a Synthesis of Morphenol," <u>J.Chem. Soc. Perkin Trans.</u> 1 pp. 1305-1311 (1988)	
	A160	Hodges et al., "Chemical and biological properties of some oxindolidyl-3-methines," <u>Canadian J. Chemistry</u> 46:2189-2194 (1968)	
	A161	Honegger et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 5:199-209 (1987)	
	A162	Houben-Weyl., "Substance Index," <u>Cyclic Compounds V Bicyclic Compounds 1</u> E231:834-1018 (1999)	
	A163	Houck et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability Genetic and Proteolytic Mechanisms," <u>J. Biol. Chem.</u> 267:26031-26037 (1992)	
	A164	Howard et al., Provisional Patent Application No. 60/015,134 filed March 29, 1996 for "Lactam Derivatives"	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	14	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A165	Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids," <u>Eur. J. Med. Chem.</u> 27:779-789 (1992)	
	A166	Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1 acetic acids" <u>Chemical Abstracts</u> , Vol. 118, abstract no. 254813 (1993)	
	A167	Hu et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," <u>Molecular and Cellular Biology</u> 12(3):981-990 (1992)	
	A168	Ijaz et al., "The Conversion of o, β -Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," <u>J. Chem. Res. (S)</u> pp. 116 (1990)	
	A169	Ijaz et al., "The Conversion of o, β -Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," <u>Chemical Abstracts</u> , Vol. 113, abstract no. 93739 (1990)	
	A170	Jellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994)	
	A171	Kashishian and Cooper, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cy1," <u>Molecular Biology of the Cell</u> 4:49-57 (1993)	
	A172	Kashishian et al., "Phosphorylation Sites in the PDGF receptor with Different Specificities for Binding GAP and P13 Kinase <i>in vivo</i> ," <u>The EMBO Journal</u> 11(4):1373-1382 (1992)	
	A173	Kato et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," <u>Journal of Chromatography</u> 616:67-71 (1993).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 <i>(use as many sheets as necessary)</i>		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	15	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A174	Katritzky et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," <u>J. Heterocyclic Chem.</u> 25:1287-1292 (1988)	
	A175	Kazlauskas et al., "The 64-kDa Protein That Associates with the Platelet-Derived Growth Factor Receptor β Subunit via Tyr-1009 Is The SH2-Containing Phosphotyrosine Phosphatase Syp," <u>Proc. Natl. Acad. Sci. USA</u> 90:6939-6942 (1993)	
	A176	Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993)	
	A177	Khalil and Abdel-Rahman, "Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes," <u>J. Indian Chem. Soc.</u> , 54:904-907 (1977)	
	A178	Kim et al., "Inhibition of Vascular endothelial growth factor-induced angiogenesis suppresses tumor growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)	
	A179	Kinsella et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <u>Exp. Cell Research</u> 199:52-62 (1992)	
	A180	Klagsburn and Soker, "VEGF/VPF: the angiogenesis factor found?" <u>Current Biology</u> 3:699-702 (1993)	
	A181	Kobayashi et al., "Anti-tumor Activity of Indole Derivatives," <u>Yakugaku Zasshi</u> 97(9):1033-1039 (1977)	
	A182	Koch et al., "SH2 and SH3 Domains: Elements that Control Interactions of Cytoplasmic Signalling Proteins," <u>Science</u> 252:668-674 (1991)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 <i>(use as many sheets as necessary)</i>		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	16	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A183	Köhler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> 256:495-497 (1975)	
	A184	Komada et al., "The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," <u>Oncogene</u> 8:2381-2390 (1993)	
	A185	Korc et al., "Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha," <u>J. Clin. Invest.</u> 90:1352-1360 (1992)	
	A186	Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity ¹ ," <u>J. Immunol. Methods</u> 64:313-320 (1983)	
	A187	Kovac and Stetinova, "Furan derivatives LXXX. Synthesis and properties of substituted furfurylidenoxindoles," <u>Chem. resu</u> 30:484-492 (1976)	
	A188	Krueger and Saito, "A human transmembrane protein-tyrosine-phosphatase, PTP, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases," <u>Proc. Natl. Acad. Sci. USA</u> 89:7417-7421 (1992)	
	A189	Kumbae et al., "Amplification of α -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633 (1992)	
	A190	Larock and Babu, "Synthesis of Nitrogen Heterocycles via Palladium-catalyzed Intramolecular Cyclization," <u>Tetrahedron Letters</u> 28:52991-52994 (1987)	
	A191	Lee and Donoghue, "Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction," <u>Journal of Cell Biology</u> 118:1057-1070 (1992)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 <i>(use as many sheets as necessary)</i>				Prior Application Number	10/076,621
				Prior Appl. Filing Date	02/19/2002
				First Named Inventor	Peng Cho TANG
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	17	of	26	Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A192	Levitzki and Gazit, "Tyrosine kinase inhibition: An approach to drug development," <u>Science</u> 267:1782-1788 (1995)		
	A193	Maas et al., "Viral resistance to the thiazolo-iso-indolines, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase," <u>Antimicrobial Agents and Chemotherapy</u> 37(12):2612-2617 (1993)		
	A194	Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," <u>Cancer Research</u> 50:2511-2517 (1990)		
	A195	Mariani et al., "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:381 at abstract no. 2268 (1994)		
	A196	Martin-Leon et al., "On the Cyclization to the Elusive Amino-4H-pyran Ring," <u>Liebigs Ann. Chem.</u> pp. 101-104 (1990)		
	A197	Millauer et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72:835-846 (1993)		
	A198	Mirand et al., "A Synthetic Entry in the <i>Aristolelia</i> Alkaloids," <u>J. Org. Chem.</u> 47:4169-4170 (1982)		
	A199	Mohammad et al., "Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors," <u>Science</u> 276:955-960 (1997)		
	A200	Moreto et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," <u>Arzneimittel-Forschung Drug Research</u> 29(II):1561-1564 (1979)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 <i>(use as many sheets as necessary)</i>		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	18	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A201	Moreto et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric Diester of 3,3 Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (Dan-603) in the Rat," <u>European Journal of Pharmacology</u> 36:221-226 (1976)	
	A202	Morrison et al., "Signal transduction from membrane to cytoplasm: Growth factors and membrane-bound oncogene products increase Raf-1 phosphorylation and associated protein kinase activity," <u>Proc. Natl. Acad. Sci. USA</u> 85:8855-8859 (1988)	
	A203	Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983)	
	A204	Neber and Rocker, "Ueber die einwirkung von benzaldehyden auf die freie o-aminophenyl-essigsäure," <u>Chem. Ber.</u> 56:1710-1717 (1923) (with translation)	
	A205	Nishimura et al., "Two Signaling Molecules Share a phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 13:6889-6896 (1993)	
	A206	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," <u>Chemical Abstracts</u> , Vol. 765, abstract no. 21121 (1972)	
	A207	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 3. Halogen-containing 9-phenanthrenemethanols," <u>Chemical Abstracts</u> , Vol. 83, abstract no. 188214 (1975)	
	A208	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," <u>J. Med. Chem.</u> 14:921-925 (1971)	
	A209	O'Sullivan and Rothery, "The Preparation and Possible Clinical Significance of 4'-Dialkylaminoisoindogenides," <u>Clinica Chimica Acta</u> 62:181-182 (1975)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	19	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A210	Osborne et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," <u>Cancer Research</u> 45:584-590 (1985)	
	A211	Ozzello and Sordat, "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," <u>Eur. J. Cancer</u> 16:553-559 (1980)	
	A212	Pavlenko et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," <u>Dopov. Akad. Nauk Ukr. RSR</u> 7:64-66 (1980)	
	A213	Plate, "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas <i>in vivo</i> ," <u>Nature</u> 359:845-848 (1992)	
	A214	Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7(6):334-339 (1994)	
	A215	Quinn et al., "Fetal Liver Kinase 1 is a Receptor for Vascular Endothelial Growth Factor and is Selectively Expressed in Vascular Endothelium," <u>Proc. Natl. Acad. Sci. USA</u> 90:7533-7537 (1993)	
	A216	Rozakis-Adcock et al., "Association of the Shc and Grb2-Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases," <u>Nature</u> 360:689-692 (1992)	
	A217	Ruveda and Gonzalez, "Geometric isomerism in benzyldeneoxindoles," <u>Spectrochimica Acta</u> 26A:1275-1277 (1970)	
	A218	Rygaard and Povlsen, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," <u>Acta path. microbiol. scand.</u> 77:758-760 (1969)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	20	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A219	Saito and Streuli, "Molecular Characterization of Protein Tyrosine Phosphatases," <u>Cell Growth & Differentiation</u> 2:59-65 (1991)	
	A220	Sandberg-Nordqvist et al., "Characterization of insulin-like growth factor 1 in human primary brain tumors," <u>Cancer Res.</u> 53:2475-2478 (1993)	
	A221	Schindler et al., "Dibenz[b,f]-azocin-Derivate," <u>Helvetica Chimica Acta</u> 49:985-989 (1966)	
	A222	Schlessinger and Ullrich, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391 (1992)	
	A223	Schnierle et al., "Vilsmeier-Reaktion mit Pyrrol- und Pyrrolon-Derivaten," <u>Liebigs Ann. Chem.</u> 715:90-97 (1968)	
	A224	Schuchter et al., "Successful Treatment of Murine Melanoma With Bryostatin 1," <u>Cancer Research</u> 51:682-687 (1991)	
	A225	Seibert et al., "Clonal Variation of MCF-7 Breast Cancer Cells <i>in Vitro</i> and in Athymic Nude Mice," <u>Cancer Research</u> 43:2223-2239 (1983)	
	A226	Shafie and Grantham, "Role of Hormones in Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted into Athymic Nude Mice," <u>J. Natl Cancer Institute</u> 67(1):51-56 (1981)	
	A227	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <u>Oncogene</u> 5:519-524 (1990)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	21	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A228	Shiraishi et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4-Hydroxycinnamamide Derivatives in Vitro," <u>Cancer Research</u> 49:2374-2378 (1989)	
	A229	Shiraishi, "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4- Hydroxycinnamamide Derivatives," <u>Biochemical and Biophysical Research Communications</u> 147:322-328 (1987)	
	A230	Shweiki et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," <u>Nature</u> 359:843-845 (1992)	
	A231	Singh et al., "Indolinone Derivatives as Potential Antimicrobial Agents," <u>Zentralbl. Mikrobiol.</u> 144:105-109 (1989)	
	A232	Singh et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxosprio (Azetidin-3', 4-Indol-2' Ones)," <u>Bollettino Chimico Farmaceutico</u> 133:76-79 (1994)	
	A233	Skehan et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," <u>J. Natl. Cancer Inst.</u> 82:1107-1112 (1990)	
	A234	Slamon et al., "Studies of the HER/2- <i>neu</i> Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989)	
	A235	Soldi et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125 ^{FAK}) in Human Endothelial Cells," <u>Oncogene</u> 13(3):515-525 (1996)	
	A236	Songyang et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," <u>Cell</u> 72:767-778 (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	22	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A237	Songyang et al., Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> 14:2777-2785 (1994)	
	A238	Spada and Myers, "Small molecule inhibitors of tyrosine kinase activity," <u>Expert Opinion on Therapeutic Patents</u> 5(8):805-817 (1995)	
	A239	Stetinova et al., "Stereochemistry and Photoisomerisation of Furfurylideneoxindoles," <u>Collection Czechoslov. Chem. Commun.</u> 42:2201-2206 (1976)	
	A240	Stolle, Beilstein Reg. No. 273650, <u>J. Prakt. Chem.</u> , Vol. 2, page 128 (1930)	
	A241	Sumpter and Miller, "Chapter IV – Oxindole," in <u>Heterocyclic Compounds With Indole and Carbazole Systems</u> , Interscience Publishers, Inc., New York, pp. 134-153 (1954)	
	A242	Sun et al., "Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases," <u>J. Med. Chem.</u> 41:2588-2603 (1998)	
	A243	Superti-Furga et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," <u>Nature Biotech</u> 14:600-605 (1996)	
	A244	Superti-Furga et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," <u>EMBO J.</u> 12:2625-2634 (1993)	
	A245	Tacconi and Marinone, "Preparazione e caratteristiche di alcuni 3-ossindolidenderivati," <u>Ricerca Scientifica</u> 38:1239-1244 (1968)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	23	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A246	Tacconi et al., "(Z)- and (E)-3-Alkylidene-1,3-dihydroindol-2-ones: Influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," <u>J.C.S. Perkin II</u> pp. 150-154 (1976)	
	A247	Takano et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C," <u>Mol. Bio. Cell</u> 4:358A (1993), at abstract no. 2076	
	A248	Terrett et al., "Combinatorial synthesis- the design of compound libraries and their application to drug discovery," <u>Tetrahedron</u> 51(30):8135-8173 (1995)	
	A249	Thompson et al., "Facile Dimerisation of 3-Benzylideneindoline-2-thiones," <u>J. Chem. Soc. Perkin Trans. (I)</u> pp. 1835-1837 (1993)	
	A250	Torp et al., "Expression of the epidermal growth factor receptor gene in human brain metastases," <u>AMPIS</u> 100:713-719 (1992)	
	A251	Traxler, "Protein tyrosine kinase inhibitors in cancer treatment," <u>Expert Opinion on Therapeutic Patents</u> 7(6):571-588 (1997)	
	A252	Treibs et al., "Uber isoindigoide Farbstoffe der Pyrrol-Reihe," <u>Liebigs Ann. Chem.</u> 702:112-130 (1967)	
	A253	Trost et al. (ed.), " <u>Comprehensive Organic Synthesis</u> ," <u>Selectivity, Strategy & Efficiency in Modern Organic Chemistry</u> 4:478 (1991)	
	A254	Tsai et al., "The Effect of 3,3-Di-Pyridyl-Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," <u>Neuropharmacology</u> 31(9):943-947 (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 <i>(use as many sheets as necessary)</i>		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	24	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A255	Tuzi et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)	
	A256	Twamley-Stein et al., "The Src Family Tyrosine Kinases are Required for Platelet-Derived Growth Factor-Mediated Signal Transduction in NIH-3T3 Cells," <u>Proc. Natl. Acad. Sci.</u> 90:7696-7700 (1993)	
	A257	Ullrich and Schlessinger, "Signal Transduction by Receptors with Tyrosine Kinase Activity," <u>Cell</u> 61:203-212 (1990)	
	A258	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem.</u> 265:19461-19466 (1990)	
	A259	Varma and Gupta, "Nucleophilic Reactions of 2-Methyl-3-(4'-carbomethoxyphenyl)-4-quinazolinones with 2-Indolinones," <u>J. Indian Chem. Soc.</u> 66:804-805 (1989)	
	A260	Voller et al., "Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2 nd edition, Rose and Friedman editors, American Society of Microbiology, Washington D.C., pp. 359-371 (1980)	
	A261	von Dobeneck et al., "α.β'-Diindolylmethane und-methene. Der Urorosein-Chromophor," <u>Zur Chemie des Indols</u> VI:1347-1357 (1969)	
	A262	Wahl et al., "Chimie Organique - Sur les iso-indogenides," <u>C.R. Hebd. Seances Acad. Sci.</u> 149:132-134 (July 1909)	
	A263	Wahl, "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," <u>Ann. Chim., Database Crossfire, Beilstein Ref. No.</u> 2-21-00-00290, p. 350 (1926)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 (use as many sheets as necessary)		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	25	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A264	Wahl, Beilstein Reg. No. 191439, <u>Bull. Soc. Chim. Fr.</u> , page 1038 (1909)	
	A265	Wahl, Beilstein Reg. No. 231732, <u>Bull. Soc. Chim. Fr.</u> , pages 1035-1038 (1909)	
	A266	Walker, "The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8(5):626-637 (1965)	
	A267	Walker, "Synthesis of a α -(p-Aminophenyl)- and α -(p-Chlorophenyl)- β -aryl-propionitriles by Catalytic Reduction of Stilbenenitriles," <u>J. Med. Chem.</u> 8(5):583-588 (1965)	
	A268	Walker, "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)- and 3-(β -Alkylaminoethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8(5):626-637 (1965)	
	A269	Warri et al., "Estrogen Suppression of <i>erbB2</i> Expression is Associated with Increased Growth Rate of ZR-75-I Human Breast Cancer Cells <i>In Vitro</i> and in Nude Mice," <u>Int. J. Cancer</u> 49:616-623 (1991)	
	A270	Weidner et al., "Tumor Angiogenesis and Metastasis -- Correlation in Invasive Breast Carcinoma," <u>New England J. Medicine</u> 324:1-7 (1991)	
	A271	Winkelmann et al., "Chemotherapeutically Active Nitro Compounds: 4. 5-Nitroimidazoles (Part I)," <u>Arzneim.-Forsch./Drug Res.</u> 27(II):2251-2263 (1977)	
	A272	Wright et al., "Cyclic Hydroxamic Acids Derived from Indole," <u>J. Amer. Chem. Soc.</u> 78:221-224 (1956)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 24, 2004 <i>(use as many sheets as necessary)</i>		Prior Application Number	10/076,621
		Prior Appl. Filing Date	02/19/2002
		First Named Inventor	Peng Cho TANG
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	26	of	26
		Attorney Docket Number	034536-1150

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A273	Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992)	
	A274	Wright, Beilstein Reg. No. 244658, <u>J. Amer. Chem. Soc.</u> 78:221-224 (1956)	
	A275	Wright, Beilstein Reg. No. 235900, <u>J. Amer. Chem. Soc.</u> 78:221-224 (1956)	
	A276	Young and Babbitt, "2-(2-Methyl-3-indolyl)-1,4-benzoquinone, A Reversible Redox Substrate at the Carbon Paste Electrode in Acidic Aqueous-Ethanol Media," <u>J. Org. Chem.</u> 47:1571-1572 (1982)	
	A277	Zaman et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β -Receptor (β -PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57(1):57-64 (1999)	
	A278	Zhang et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," <u>Molecular Pharmacology</u> 49:288-294 (1996)	
	A279	Zhungietu et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," <u>Institute of Chemistry, Academy of Science of the Moldavian SSR, Kishinev pp. 34-37 translated from Khimiya Geterotsiklicheskikh Soedinenii</u> 1:40-44 (1973)	
	A280	Zhungietu et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," <u>Chemical Abstracts</u> , Vol. 78, abstract no. 111201 (1973)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.